PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 15009110-8 2004 An RNase protection assay (RPA) showed that expression of tumor necrosis factor-alpha (TNF-alpha) and -beta were inhibited by anthralin upon successful treatment. Anthralin 126-135 tumor necrosis factor Mus musculus 58-85 15802490-5 2005 We show that anthralin disrupts mitochondrial membrane potential (DeltaPsim) and causes endogenous cytochrome c release, resulting in the activation of caspase-3 and characteristic morphological changes of apoptosis. Anthralin 13-22 cytochrome c, somatic Homo sapiens 99-111 15802490-5 2005 We show that anthralin disrupts mitochondrial membrane potential (DeltaPsim) and causes endogenous cytochrome c release, resulting in the activation of caspase-3 and characteristic morphological changes of apoptosis. Anthralin 13-22 caspase 3 Homo sapiens 152-161 15009100-2 2004 In contrast to a previous report, we found that anthralin induced time- and concentration-dependent phosphorylation of epidermal growth factor receptor in primary human keratinocytes. Anthralin 48-57 epidermal growth factor receptor Homo sapiens 119-151 15009100-5 2004 Second, there is a correlation between a time-dependent increase in anthralin-induced epidermal growth factor receptor phosphorylation and H(2)O(2) generation. Anthralin 68-77 epidermal growth factor receptor Homo sapiens 86-118 15009100-6 2004 Third, the structurally different antioxidants n-propyl gallate and N-acetylcysteine inhibited epidermal growth factor receptor phosphorylation induced by anthralin. Anthralin 155-164 epidermal growth factor receptor Homo sapiens 95-127 15009100-8 2004 The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2. Anthralin 91-100 epidermal growth factor receptor Homo sapiens 4-36 15009100-8 2004 The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2. Anthralin 91-100 epidermal growth factor receptor Homo sapiens 109-141 15009100-10 2004 Our data identify anthralin-induced reactive oxygen species and, more specifically, H(2)O(2) as an important upstream mediator required for ligand-independent epidermal growth factor receptor phosphorylation and downstream signaling. Anthralin 18-27 epidermal growth factor receptor Homo sapiens 159-191 16141522-1 2005 We performed this study to determine the relationship between activation of nuclear factor (NF)-kappaB and inhibition of keratinocyte growth by anthralin, which not only might be useful for a better understanding of the role of NF-kappaB in the pathogenesis of psoriasis, but also indicate whether the inflammatory reaction induced by anthralin is inseparable from its antipsoriatic activity. Anthralin 144-153 nuclear factor kappa B subunit 1 Homo sapiens 76-102 16141522-1 2005 We performed this study to determine the relationship between activation of nuclear factor (NF)-kappaB and inhibition of keratinocyte growth by anthralin, which not only might be useful for a better understanding of the role of NF-kappaB in the pathogenesis of psoriasis, but also indicate whether the inflammatory reaction induced by anthralin is inseparable from its antipsoriatic activity. Anthralin 144-153 nuclear factor kappa B subunit 1 Homo sapiens 228-237 16141522-1 2005 We performed this study to determine the relationship between activation of nuclear factor (NF)-kappaB and inhibition of keratinocyte growth by anthralin, which not only might be useful for a better understanding of the role of NF-kappaB in the pathogenesis of psoriasis, but also indicate whether the inflammatory reaction induced by anthralin is inseparable from its antipsoriatic activity. Anthralin 335-344 nuclear factor kappa B subunit 1 Homo sapiens 76-102 16141522-2 2005 The involvement of NF-kappaB was assessed using the antipsoriatic drugs leflunomide and triptolide (T0) as effectors, since they can inhibit NF-kappaB activation induced by anthralin. Anthralin 173-182 nuclear factor kappa B subunit 1 Homo sapiens 19-28 16141522-2 2005 The involvement of NF-kappaB was assessed using the antipsoriatic drugs leflunomide and triptolide (T0) as effectors, since they can inhibit NF-kappaB activation induced by anthralin. Anthralin 173-182 nuclear factor kappa B subunit 1 Homo sapiens 141-150 16141522-5 2005 Thus it might be possible to inhibit the inflammatory response induced by anthralin via repression of NF-kappaB activation. Anthralin 74-83 nuclear factor kappa B subunit 1 Homo sapiens 102-111 16141522-6 2005 We found that leflunomide or T0 could significantly inhibit the mRNA overexpression of interleukin-8 and intercellular adhesion molecule-1 in keratinocytes induced by anthralin. Anthralin 167-176 C-X-C motif chemokine ligand 8 Homo sapiens 87-138 16141522-7 2005 Taken together, our data indicate that the growth inhibition of anthralin is related to the NF-kappaB-independent signaling pathway, and that leflunomide or T0 could control proinflammatory cytokine expression induced by anthralin via inhibiting the activation of NF-kappaB. Anthralin 64-73 nuclear factor kappa B subunit 1 Homo sapiens 92-101 15009110-8 2004 An RNase protection assay (RPA) showed that expression of tumor necrosis factor-alpha (TNF-alpha) and -beta were inhibited by anthralin upon successful treatment. Anthralin 126-135 tumor necrosis factor Mus musculus 87-96 14602527-3 2003 TGFbeta concentrations were measured in the plasma of 26 patients with psoriasis using an enzyme immunoassay and analysed with respect to the psoriasis area and severity index (PASI) before and after treatment with salicylic acid and/or sulphur followed by dithranol ointment. Anthralin 257-266 transforming growth factor beta 1 Homo sapiens 0-7 12666446-0 2002 [Influence of dithranol therapy on clinical status and serum calcitonin concentrations in patients with common psoriasis]. Anthralin 14-23 calcitonin related polypeptide alpha Homo sapiens 61-71 12895001-7 2003 These experiments showed that expression of tumor necrosis factor-alpha and interferon-gamma was inhibited by anthralin, whereas expression of interleukin-1alpha/beta and their receptor antagonist, interleukin-1Ra, and interleukin-10 was stimulated by anthralin. Anthralin 110-119 tumor necrosis factor Rattus norvegicus 44-71 12895001-7 2003 These experiments showed that expression of tumor necrosis factor-alpha and interferon-gamma was inhibited by anthralin, whereas expression of interleukin-1alpha/beta and their receptor antagonist, interleukin-1Ra, and interleukin-10 was stimulated by anthralin. Anthralin 110-119 interferon gamma Rattus norvegicus 76-92 12895001-7 2003 These experiments showed that expression of tumor necrosis factor-alpha and interferon-gamma was inhibited by anthralin, whereas expression of interleukin-1alpha/beta and their receptor antagonist, interleukin-1Ra, and interleukin-10 was stimulated by anthralin. Anthralin 252-261 tumor necrosis factor Rattus norvegicus 44-71 12895001-7 2003 These experiments showed that expression of tumor necrosis factor-alpha and interferon-gamma was inhibited by anthralin, whereas expression of interleukin-1alpha/beta and their receptor antagonist, interleukin-1Ra, and interleukin-10 was stimulated by anthralin. Anthralin 252-261 interferon gamma Rattus norvegicus 76-92 12804984-0 2003 Lack of upregulation of epidermal fatty acid binding protein in dithranol induced irritation. Anthralin 64-73 fatty acid binding protein 5 Homo sapiens 24-60 12804984-6 2003 The expression of E-FABP in dithranol irritation correlates with the unimpaired skin barrier function as assessed by measurements of TEWL. Anthralin 28-37 fatty acid binding protein 5 Homo sapiens 18-24 12542536-2 2003 Previously, it was shown that in cultured keratinocytes, elafin expression is induced by serum or tumor necrosis factor-alpha, and that expression is suppressed by retinoids, dithranol, and p38 mitogen-activated protein kinase inhibitors. Anthralin 175-184 peptidase inhibitor 3 Homo sapiens 57-63 12566829-0 2003 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Anthralin 132-141 BCL2 apoptosis regulator Homo sapiens 32-37 12566829-0 2003 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Anthralin 132-141 BCL2 like 1 Homo sapiens 39-44 12566829-0 2003 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Anthralin 132-141 BCL2 associated X, apoptosis regulator Homo sapiens 46-49 12566829-0 2003 Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Anthralin 132-141 Fas ligand Homo sapiens 60-70 12566829-6 2003 Immunohistochemical examination revealed that psoriatic keratinocytes expressed high levels of Bcl-x, which was significantly reduced after anthralin treatment. Anthralin 140-149 BCL2 like 1 Homo sapiens 95-100 12566829-7 2003 Bax was not detected in the epidermal keratinocytes in the petrolatum-treated skin, while it was present in the upper keratinocytes after anthralin therapy. Anthralin 138-147 BCL2 associated X, apoptosis regulator Homo sapiens 0-3 12566829-8 2003 Bcl-2 was detected only in basal layers of psoriatic epidermis following both petrolatum and anthralin application. Anthralin 93-102 BCL2 apoptosis regulator Homo sapiens 0-5 12666446-1 2002 The aim of this work was to study the effects of external dithranol therapy of psoriatic patients on the clinical status and serum calcitonin concentrations. Anthralin 58-67 calcitonin related polypeptide alpha Homo sapiens 131-141 12666446-7 2002 After a 14-day dithranol therapy a significant calcitonin concentration decrease as well as clinical effects were observed in the investigated group. Anthralin 15-24 calcitonin related polypeptide alpha Homo sapiens 47-57 11464104-0 2001 Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro. Anthralin 0-9 interferon gamma Homo sapiens 44-60 12218287-5 2002 All-trans-retinoic acid, dithranol and the p38 mitogen-activated protein (MAP) kinase inhibitor SB220025 displayed a strong inhibitory effect on SKALP expression while cyclosporin A, dexamethasone, the vitamin D(3) derivative calcipotriol and the p38 MAP kinase inhibitor SB203580 showed only moderate inhibition. Anthralin 25-34 peptidase inhibitor 3 Homo sapiens 145-150 12218287-5 2002 All-trans-retinoic acid, dithranol and the p38 mitogen-activated protein (MAP) kinase inhibitor SB220025 displayed a strong inhibitory effect on SKALP expression while cyclosporin A, dexamethasone, the vitamin D(3) derivative calcipotriol and the p38 MAP kinase inhibitor SB203580 showed only moderate inhibition. Anthralin 25-34 mitogen-activated protein kinase 14 Homo sapiens 247-261 11464104-0 2001 Dithranol and dimethylfumarate suppress the interferon-gamma-induced up-regulation of cytokeratin 17 as a putative psoriasis autoantigen in vitro. Anthralin 0-9 keratin 17 Homo sapiens 86-100 11464104-5 2001 Preincubation with a subcytotoxic and antiproliferative dithranol concentration as low as 0.3 microM for 2 h prior to the IFN-gamma exposure resulted in a K17 expression that was significantly lower than the IFN-gamma-induced K17 expression reference level. Anthralin 56-65 interferon gamma Homo sapiens 122-131 11464104-5 2001 Preincubation with a subcytotoxic and antiproliferative dithranol concentration as low as 0.3 microM for 2 h prior to the IFN-gamma exposure resulted in a K17 expression that was significantly lower than the IFN-gamma-induced K17 expression reference level. Anthralin 56-65 keratin 17 Homo sapiens 155-158 11464104-5 2001 Preincubation with a subcytotoxic and antiproliferative dithranol concentration as low as 0.3 microM for 2 h prior to the IFN-gamma exposure resulted in a K17 expression that was significantly lower than the IFN-gamma-induced K17 expression reference level. Anthralin 56-65 interferon gamma Homo sapiens 208-217 11464104-5 2001 Preincubation with a subcytotoxic and antiproliferative dithranol concentration as low as 0.3 microM for 2 h prior to the IFN-gamma exposure resulted in a K17 expression that was significantly lower than the IFN-gamma-induced K17 expression reference level. Anthralin 56-65 keratin 17 Homo sapiens 226-229 11235021-2 2001 Since interleukin-8 and interleukin-10 are involved in the pathogenesis of psoriasis, the aim of our study was to investigate the effect of dithranol on interleukin-8, interleukin-10 mRNA production and interleukin-10 receptor expression of the HaCaT keratinocyte cell line which is commonly used in experiments examining the effects of therapeutic drugs on keratinocytes. Anthralin 140-149 C-X-C motif chemokine ligand 8 Homo sapiens 153-166 11235021-8 2001 Depending on the concentration dithranol increased the mRNA production of interleukin-10 receptors in HaCaT cells. Anthralin 31-40 interleukin 10 Homo sapiens 74-88 11235021-0 2001 Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Anthralin 0-9 interleukin 10 Homo sapiens 22-27 11235021-9 2001 This dithranol induced dose dependent upregulation of IL-10 receptors in HaCaT cells was also observed on the protein level using immunohistochemistry. Anthralin 5-14 interleukin 10 Homo sapiens 54-59 10326864-3 1999 A single treatment with three different tumor promoters (12-O-tetradecanoylphorbol-13-acetate (TPA), anthralin, and thapsigargin) induced IL-1Ra mRNA with different kinetics in mouse skin. Anthralin 101-110 interleukin 1 receptor antagonist Mus musculus 138-144 10807949-1 2000 The effects of two antipsoriatic compounds, calcipotriol and anthralin, separately or in combination on ribonuclease P (RNase P), were investigated using a cell-free system from the slime mold Dictyostelium discoideum. Anthralin 61-70 RnpB Schizosaccharomyces pombe 120-127 10807949-5 2000 Calcipotriol or anthralin alone exerted a dose-dependent inhibitory effect on RNase P activity, with the former being more active than the latter in this respect. Anthralin 16-25 RnpB Schizosaccharomyces pombe 78-85 10233310-9 1999 PKC alpha was downregulated initially, and was then elevated from 3 days after anthralin treatment and 14 days after SDS application. Anthralin 79-88 protein kinase C, alpha Mus musculus 0-9 10233310-10 1999 PKC beta was unchanged initially, decreased at 8 and 14 days after anthralin and SDS treatment, respectively, and reverted to the control level at 25 days after anthralin treatment, when it was still lower than the control in SDS-treated skin. Anthralin 67-76 protein kinase C, beta Mus musculus 0-8 10233310-10 1999 PKC beta was unchanged initially, decreased at 8 and 14 days after anthralin and SDS treatment, respectively, and reverted to the control level at 25 days after anthralin treatment, when it was still lower than the control in SDS-treated skin. Anthralin 161-170 protein kinase C, beta Mus musculus 0-8 10233310-11 1999 PKC delta was also unchanged at first, but was elevated from 3 days after anthralin treatment and 14 days after SDS application. Anthralin 74-83 protein kinase C, delta Mus musculus 0-9 10828315-8 2000 Various studies have shown that by altering the structure of anthralin the in vitro profile can be markedly altered from an only moderate 5-lipoxygenase inhibitor to a more potent inhibitor of this enzyme, which may reflect improved activity against the inflammatory component of psoriasis while the antiproliferative activity is retained. Anthralin 61-70 arachidonate 5-lipoxygenase Homo sapiens 138-152 10733674-0 2000 Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes. Anthralin 20-29 mitogen-activated protein kinase 8 Homo sapiens 40-43 10733674-4 2000 We demonstrate that anthralin exerts potent effects on keratinocytes and mononuclear cells through strong induction of lipid peroxidation and JNK activation, a stress-induced signal transduction pathway. Anthralin 20-29 mitogen-activated protein kinase 8 Homo sapiens 142-145 10733674-6 2000 JNK activation was detected in peripheral blood mononuclear cells at a 40-fold lower anthralin dose compared with keratinocytes. Anthralin 85-94 mitogen-activated protein kinase 8 Homo sapiens 0-3 10733674-8 2000 This study demonstrates that mononuclear leukocytes are markedly more sensitive than keratinocytes to anthralin-induced lipid peroxidation and JNK activation. Anthralin 102-111 mitogen-activated protein kinase 8 Homo sapiens 143-146 10733674-9 2000 We identify anthralin as a novel and potent inducer of JNK activation and demonstrate that this process is mediated, at least in part, by lipid peroxidation which is among the earliest and most proximate, membrane-related responses to anthralin yet described. Anthralin 12-21 mitogen-activated protein kinase 8 Homo sapiens 55-58 10733674-9 2000 We identify anthralin as a novel and potent inducer of JNK activation and demonstrate that this process is mediated, at least in part, by lipid peroxidation which is among the earliest and most proximate, membrane-related responses to anthralin yet described. Anthralin 235-244 mitogen-activated protein kinase 8 Homo sapiens 55-58 10188141-2 1999 The present study was undertaken to clarify whether the serum level of EGF is correlated with the disease activity during local therapy with dithranol in psoriasis. Anthralin 141-150 epidermal growth factor Homo sapiens 71-74 10073141-1 1999 1,8-Dihydroxy-9(10H)-anthracenones with a 10-alpha-aminoacyl group were synthesized using either a mixed-anhydride coupling method or Boc-protected oxazolidinediones. Anthralin 0-34 BOC cell adhesion associated, oncogene regulated Homo sapiens 134-137 10188141-3 1999 We examined serum EGF concentrations in acute and chronic psoriasis before and after topical treatment with dithranol and the correlation with Psoriasis Activity and Severity Index (PASI). Anthralin 108-117 epidermal growth factor Homo sapiens 18-21 9553912-0 1998 Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. Anthralin 109-118 interferon gamma Homo sapiens 25-34 9628260-5 1998 RESULTS: Anthralin, at concentrations between 5 microM and 25 microM, caused a marked increase in granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-6, IL-8 and TNFalpha synthesis that was selectively inhibited by specific antioxidants. Anthralin 9-18 colony stimulating factor 2 Homo sapiens 98-146 9628260-5 1998 RESULTS: Anthralin, at concentrations between 5 microM and 25 microM, caused a marked increase in granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-6, IL-8 and TNFalpha synthesis that was selectively inhibited by specific antioxidants. Anthralin 9-18 colony stimulating factor 2 Homo sapiens 148-154 9628260-5 1998 RESULTS: Anthralin, at concentrations between 5 microM and 25 microM, caused a marked increase in granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-6, IL-8 and TNFalpha synthesis that was selectively inhibited by specific antioxidants. Anthralin 9-18 interleukin 6 Homo sapiens 157-175 9628260-5 1998 RESULTS: Anthralin, at concentrations between 5 microM and 25 microM, caused a marked increase in granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-6, IL-8 and TNFalpha synthesis that was selectively inhibited by specific antioxidants. Anthralin 9-18 C-X-C motif chemokine ligand 8 Homo sapiens 177-181 9628260-5 1998 RESULTS: Anthralin, at concentrations between 5 microM and 25 microM, caused a marked increase in granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin (IL)-6, IL-8 and TNFalpha synthesis that was selectively inhibited by specific antioxidants. Anthralin 9-18 tumor necrosis factor Homo sapiens 186-194 9715255-5 1998 Maximum ear swelling induced by anthralin coincided with the elevation of cytokine mRNA expression in the skin, including interleukin-6, granulocyte-macrophage colony-stimulating factor, macrophage inflammatory protein-2, and tumor necrosis factor alpha at 24 h post challenge. Anthralin 32-41 interleukin 6 Mus musculus 122-135 9715255-5 1998 Maximum ear swelling induced by anthralin coincided with the elevation of cytokine mRNA expression in the skin, including interleukin-6, granulocyte-macrophage colony-stimulating factor, macrophage inflammatory protein-2, and tumor necrosis factor alpha at 24 h post challenge. Anthralin 32-41 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 137-220 9715255-5 1998 Maximum ear swelling induced by anthralin coincided with the elevation of cytokine mRNA expression in the skin, including interleukin-6, granulocyte-macrophage colony-stimulating factor, macrophage inflammatory protein-2, and tumor necrosis factor alpha at 24 h post challenge. Anthralin 32-41 tumor necrosis factor Mus musculus 226-253 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 0-9 interleukin 6 Homo sapiens 67-71 9649716-0 1998 Immunocytochemical demonstration of reduced Cu,Zn-superoxide dismutase levels following topical application of dithranol and sodium lauryl sulphate: an indication of the role of oxidative stress in acute irritant contact dermatitis. Anthralin 111-120 superoxide dismutase 1 Homo sapiens 44-70 9649716-3 1998 Analysis of biopsies from patch test sites revealed that significant reductions in the epidermal levels of Cu,Zn-superoxide dismutase were induced by both dithranol and sodium lauryl sulphate, although the time course of diminished activity was different for each irritant. Anthralin 155-164 superoxide dismutase 1 Homo sapiens 107-133 9155955-9 1997 The results show a dose-dependent inhibition of MO IL-6, IL-8, and TNF-alpha release with a half-maximal inhibitory concentration of 0.25-0.6 microgram/ml of anthralin. Anthralin 158-167 tumor necrosis factor Homo sapiens 67-76 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 0-9 C-X-C motif chemokine ligand 8 Homo sapiens 73-77 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 0-9 tumor necrosis factor Homo sapiens 82-91 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 11-20 interleukin 6 Homo sapiens 67-71 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 11-20 C-X-C motif chemokine ligand 8 Homo sapiens 73-77 9155955-0 1997 Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Anthralin 11-20 tumor necrosis factor Homo sapiens 82-91 9155955-9 1997 The results show a dose-dependent inhibition of MO IL-6, IL-8, and TNF-alpha release with a half-maximal inhibitory concentration of 0.25-0.6 microgram/ml of anthralin. Anthralin 158-167 interleukin 6 Homo sapiens 51-55 9155955-9 1997 The results show a dose-dependent inhibition of MO IL-6, IL-8, and TNF-alpha release with a half-maximal inhibitory concentration of 0.25-0.6 microgram/ml of anthralin. Anthralin 158-167 C-X-C motif chemokine ligand 8 Homo sapiens 57-61 7545705-11 1995 Slow responders had a significantly lower severity index, a thinner epidermis, fewer CD8+ cells, and fewer proliferating keratinocytes on the anthralin-treated side than on the non-anthralin-treated side. Anthralin 142-151 CD8a molecule Homo sapiens 85-88 8989914-6 1996 Of the other promoters examined, anthralin (5 microM), benzoyl peroxide (10 microM), and okadaic acid (1 microM) induced PGHS-2 mRNA with different kinetics and to different extents. Anthralin 33-42 prostaglandin-endoperoxide synthase 2 Mus musculus 121-127 8666828-0 1996 Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. Anthralin 20-29 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 61-71 8666828-4 1996 In this study, we show that at little as 10 microM anthralin can activate a prototypic form of transcription factor NF-(kappa)B, a central transcriptional regulator of inflammatory and immune responses. Anthralin 51-60 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 116-127 8666828-5 1996 Two different lines of evidence show that ROIs, in particular H2O2, are second messengers for the anthralin-induced NF-(kappa)B activation. Anthralin 98-107 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 116-127 8666828-8 1996 Our data suggest that ROI-induced NF-(kappa)B plays a role in the anti-psoriatic activity of the drug anthralin. Anthralin 102-111 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 34-45 8849331-5 1995 Although anthralin and hypericin both inhibited the mitogenic effect of EGF in NR6/HER cells (IC50S = 100 nM and 10 microM, respectively), they also had comparable effects on DNA synthesis in response to acidic fibroblast growth factor (aFGF) and platelet-derived growth factor (PDGF). Anthralin 9-18 epidermal growth factor Homo sapiens 72-75 8849331-7 1995 We conclude that, although anthralin and hypericin both inhibit EGF signalling, they do not act specifically on the EGF-R pathway. Anthralin 27-36 epidermal growth factor Homo sapiens 64-67 7636313-7 1995 Furthermore, p21WAF1/CIP1 expression was induced in skin after sellotape stripping and by the application of agents, such as dithranol, that are capable of inducing hyperproliferation. Anthralin 125-134 cyclin dependent kinase inhibitor 1A Homo sapiens 21-25 7665919-5 1995 Northern blot analysis indicated that topical application of TPA, anthralin, mezerein, or benzoyl peroxide to SENCAR mice resulted in an increased expression of epidermal IL-1 alpha mRNA. Anthralin 66-75 interleukin 1 alpha Mus musculus 171-181 7665919-9 1995 Preapplication of GTP was also found to afford inhibition against anthralin-, benzoyl peroxide-, and mezerein-caused increased expression of epidermal IL-1 alpha mRNA and protein. Anthralin 66-75 interleukin 1 alpha Mus musculus 151-161 9101236-1 1995 In DMSO solution, anthralin and its C-10 monosubstituted derivatives reduce nitroxides to the corresponding hydroxylamine derivatives, which are not further transformed. Anthralin 18-27 homeobox C10 Homo sapiens 36-40 9101236-3 1995 It is faster in DMSO than in DMF, piperidine type of nitroxides are reduced faster than the pyrrolidine type, and the substitution on C-10 of anthralin has a significant influence on the reaction rate. Anthralin 142-151 homeobox C10 Homo sapiens 134-138 9101236-4 1995 Anthralin derivatives without protons at C-10 are not able to reduce nitroxides. Anthralin 0-9 homeobox C10 Homo sapiens 41-45 7520353-3 1994 Anthralin stimulated IL-1 alpha production in primary cultured mouse epidermal cells, and the peak IL-1 alpha level was observed at 6 h after the stimulation. Anthralin 0-9 interleukin 1 alpha Mus musculus 21-31 7719116-5 1995 Pretreatment with 0.2% Anthralin, 1% propyl gallate and 2% 3,4-hexaalkylbenzoylacrylic acid, an experimental phospholipase-A2 inhibitor, also revealed significant inhibition effects of epidermal AgNOR expression. Anthralin 23-32 phospholipase A2, group IB, pancreas Mus musculus 109-125 7930673-9 1994 Dithranol (1 microgram/microliter, n = 8), sodium dodecylsulphate (5%, n = 4), and retinoic acid (0.5%, n = 4), applied for 48 h, caused erythema, significantly increased p53 protein levels (p < 0.05), and also increased p53 mRNA. Anthralin 0-9 tumor protein p53 Homo sapiens 171-174 7930673-9 1994 Dithranol (1 microgram/microliter, n = 8), sodium dodecylsulphate (5%, n = 4), and retinoic acid (0.5%, n = 4), applied for 48 h, caused erythema, significantly increased p53 protein levels (p < 0.05), and also increased p53 mRNA. Anthralin 0-9 tumor protein p53 Homo sapiens 224-227 7520353-3 1994 Anthralin stimulated IL-1 alpha production in primary cultured mouse epidermal cells, and the peak IL-1 alpha level was observed at 6 h after the stimulation. Anthralin 0-9 interleukin 1 alpha Mus musculus 99-109 7520353-4 1994 Anthralin also stimulated IL-1 alpha release into culture medium. Anthralin 0-9 interleukin 1 alpha Mus musculus 26-36 8088360-3 1994 Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected. Anthralin 42-51 C-X-C motif chemokine ligand 8 Homo sapiens 88-101 8088360-3 1994 Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected. Anthralin 42-51 C-X-C motif chemokine ligand 8 Homo sapiens 149-162 8095749-0 1993 Down-regulation of epidermal growth factor receptors by dithranol. Anthralin 56-65 epidermal growth factor Homo sapiens 19-42 8095749-3 1993 After treatment of cells with dithranol or its therapeutically inactive oxidation product, danthrone, radioligand binding assays were performed with 125I-EGF. Anthralin 30-39 epidermal growth factor Homo sapiens 154-157 8095749-4 1993 In therapeutically active concentrations (0.25-1 micrograms/ml) dithranol induced a decrease in EGF binding in a dose dependent manner. Anthralin 64-73 epidermal growth factor Homo sapiens 96-99 8095749-7 1993 The down-regulation of EGF receptors on epidermal cells by dithranol may contribute to its antipsoriatic action. Anthralin 59-68 epidermal growth factor Homo sapiens 23-26 1596871-1 1992 Anthralin, iodoacetic acid, BHT, Tween 60 and TPA induced cytoplasmic accumulation of transcripts of the proliferin gene family at or near effective concentrations for promotion of morphological transformation of C3H/10T1/2 cells. Anthralin 0-9 prolactin family 2, subfamily c, member 2 Mus musculus 105-115 8435107-5 1993 Of the other promoters tested, anthralin (22.6 micrograms), mezerein (2 micrograms), calcium ionophore A23187 (120 micrograms), and benzoyl peroxide (20 mg) induced IL-1 alpha mRNA with different kinetics and to different extents. Anthralin 31-40 interleukin 1 alpha Mus musculus 165-175 1804060-0 1991 Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy. Anthralin 0-9 arachidonate 5-lipoxygenase Homo sapiens 37-51 1314863-0 1992 Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. Anthralin 0-9 transforming growth factor alpha Homo sapiens 33-42 1314863-7 1992 Northern analysis of anthralin-treated keratinocytes demonstrated a marked decrease in TGF-alpha mRNA expression. Anthralin 21-30 transforming growth factor alpha Homo sapiens 87-96 1314863-8 1992 Anthralin-treated keratinocytes showed decreased binding of 125I-EGF and 125I-IGF-I to their respective receptors, but EGF receptor binding was inhibited to a greater extent. Anthralin 0-9 insulin like growth factor 1 Homo sapiens 78-83 1804060-1 1991 Inhibition of 5-lipoxygenase by anthralin (1) and 41 derivatives is determined: the acids 38 and 39, the lactones 40-42 and 9-anthrone (8) are the most potent inhibitors, the lactone 41 reaching the efficacy of nordihydroguaiaretic acid (NDGA). Anthralin 32-41 arachidonate 5-lipoxygenase Homo sapiens 14-28 1810265-10 1991 The results suggest that .O2- is the potent species towards G6-PDH, if dithranol acts through formation of active oxygen species. Anthralin 71-80 glucose-6-phosphate dehydrogenase Homo sapiens 60-66 1810265-1 1991 Inhibition of glucose-6-phosphate dehydrogenase (G6-PDH) by dithranol (anthralin, CAS 480-22-8) has been studied in the presence of catalase, superoxide dismutase (SOD) and various scavengers of active oxygen species. Anthralin 60-69 glucose-6-phosphate dehydrogenase Homo sapiens 14-47 1810265-1 1991 Inhibition of glucose-6-phosphate dehydrogenase (G6-PDH) by dithranol (anthralin, CAS 480-22-8) has been studied in the presence of catalase, superoxide dismutase (SOD) and various scavengers of active oxygen species. Anthralin 60-69 glucose-6-phosphate dehydrogenase Homo sapiens 49-55 2209005-5 1990 In the MEST, with both CF-1 and Balb/c mice, dithranol caused less swelling of the test ear after challenge than butantrone. Anthralin 45-54 mesoderm specific transcript Mus musculus 7-11 1810265-1 1991 Inhibition of glucose-6-phosphate dehydrogenase (G6-PDH) by dithranol (anthralin, CAS 480-22-8) has been studied in the presence of catalase, superoxide dismutase (SOD) and various scavengers of active oxygen species. Anthralin 71-80 glucose-6-phosphate dehydrogenase Homo sapiens 14-47 1810265-1 1991 Inhibition of glucose-6-phosphate dehydrogenase (G6-PDH) by dithranol (anthralin, CAS 480-22-8) has been studied in the presence of catalase, superoxide dismutase (SOD) and various scavengers of active oxygen species. Anthralin 71-80 glucose-6-phosphate dehydrogenase Homo sapiens 49-55 1810265-3 1991 The combined addition of catalase and SOD as well as the heat-denatured enzymes and the oxygen radical scavengers alpha-tocopherol and salicylic acid markedly reduced the inhibitory effect of dithranol. Anthralin 192-201 catalase Homo sapiens 25-33 1810265-3 1991 The combined addition of catalase and SOD as well as the heat-denatured enzymes and the oxygen radical scavengers alpha-tocopherol and salicylic acid markedly reduced the inhibitory effect of dithranol. Anthralin 192-201 superoxide dismutase 1 Homo sapiens 38-41 1701190-4 1990 Statistically significant decreases in the epidermal density of CD1+ cells occurred in the responses to dithranol (p less than 0.05) and nonanoic acid (p less than 0.01). Anthralin 104-113 CD1c molecule Homo sapiens 64-67 1701190-6 1990 Alterations in the length of the dendritic processes of CD1+ cells were also induced, and semi-quantitative analysis revealed significant decreases in dendrite length in the reactions to sodium lauryl sulphate (p less than 0.05), nonanoic acid (p less than 0.001), croton oil (p less than 0.05), and dithranol (p less than 0.005). Anthralin 300-309 CD1c molecule Homo sapiens 56-59 2128944-4 1990 However, when anthralin was administered for 7 days following the treatment with 400 nmol of DMBA, the suppressive effect could be transferred with Thy-1 and Lyt-2 positive spleen cells whereas the suppressive effect by the painting of anthralin only for 7 days could not be transferred with the spleen cells. Anthralin 14-23 thymus cell antigen 1, theta Mus musculus 148-153 2128944-4 1990 However, when anthralin was administered for 7 days following the treatment with 400 nmol of DMBA, the suppressive effect could be transferred with Thy-1 and Lyt-2 positive spleen cells whereas the suppressive effect by the painting of anthralin only for 7 days could not be transferred with the spleen cells. Anthralin 14-23 CD8 antigen, alpha chain Mus musculus 158-163 2680915-4 1989 In this study we evaluated by direct-immunofluorescence and by immunoperoxidase staining using rabbit antihuman filaggrin antiserum localization of filaggrin in psoriatic skin and in normal human skin before and after treatment with anthralin 0.1%, betamethasone 0.05% and hydrocolloid dressing. Anthralin 233-242 filaggrin Homo sapiens 148-157 1980981-7 1990 In contrast, CP and CT had a synergistic effect on the dithranol-induced induction of ALP. Anthralin 55-64 alkaline phosphatase, placental Homo sapiens 86-89 26224876-8 2015 Knock-in mice expressing an uncleavable p120 RasGAP mutant showed exaggerated NF-kappaB activation when their epidermis was treated with anthralin, a drug used for the treatment of psoriasis. Anthralin 137-146 RAS p21 protein activator 1 Mus musculus 40-51 26224876-8 2015 Knock-in mice expressing an uncleavable p120 RasGAP mutant showed exaggerated NF-kappaB activation when their epidermis was treated with anthralin, a drug used for the treatment of psoriasis. Anthralin 137-146 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 78-87 2543582-6 1989 Induction of inflammatory and hyperproliferative changes in the skin by topical dithranol treatment, UVB irradiation or scotch tape stripping also induced a significant increase of CRABP 3 days after exposure. Anthralin 80-89 cellular retinoic acid binding protein 1 Homo sapiens 181-186 2529149-0 1989 Calmodulin inhibition by anthralin? Anthralin 25-34 calmodulin 1 Homo sapiens 0-10 2529819-4 1989 The results provide evidence of the coinvolvement of PAF, prostaglandins, histamine, and reactive oxygen radicals in dithranol-induced irritative dermatitis in mice. Anthralin 117-126 patchy fur Mus musculus 53-56 2529149-4 1989 Therefore we investigated the possible CaM inhibition by the antipsoriatic drug anthralin in vitro and in vivo. Anthralin 80-89 calmodulin 1 Homo sapiens 39-42 2529149-5 1989 For in vitro studies, anthralin (0.44 mM) effects on the CaM-dependent Ca++-ATPase of CaM-depleted erythrocyte ghosts were assessed. Anthralin 22-31 calmodulin 1 Homo sapiens 57-60 2529149-5 1989 For in vitro studies, anthralin (0.44 mM) effects on the CaM-dependent Ca++-ATPase of CaM-depleted erythrocyte ghosts were assessed. Anthralin 22-31 calmodulin 1 Homo sapiens 86-89 3241812-0 1988 [Fumaryldithranol and sorbyldithranol: synthesis and glucose-6-phosphate-dehydrogenase antagonism in extended 10-acylation products in the antipsoriatic dithranol. Anthralin 8-17 glucose-6-phosphate dehydrogenase Homo sapiens 53-86 3402040-1 1988 The present study was designed to compare the skin tumor promoting and epidermal ornithine decarboxylase (ODC) inducing activities of various structural analogs of anthralin (1,8-dihydroxy-9-anthrone) and chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone). Anthralin 164-173 ornithine decarboxylase, structural 1 Mus musculus 106-109 3402040-12 1988 The ability of C10-substituted derivatives of anthralin to undergo base catalyzed oxidation in vitro correlated with both ODC inducing and tumor promoting activities. Anthralin 46-55 ornithine decarboxylase, structural 1 Mus musculus 122-125 3677072-0 1987 Inhibition by retinoids of anthralin-induced mouse epidermal ornithine decarboxylase activity and anthralin-promoted skin tumor formation. Anthralin 27-36 ornithine decarboxylase, structural 1 Mus musculus 61-84 3676090-3 1987 Catalase (50-100 units/ml) protected both PMNL migration and MNL proliferation from dithranol whilst ascorbate and cysteine (1 mM), which maintain dithranol in the biologically active reduced state, potentiated the inhibition. Anthralin 84-93 catalase Homo sapiens 0-8 3677072-5 1987 Comparison of the doses of retinoids required to inhibit anthralin-induced ornithine decarboxylase by 50% and those required to inhibit anthralin-induced tumor promotion by 50% demonstrated that these values correlated. Anthralin 57-66 ornithine decarboxylase, structural 1 Mus musculus 75-98 2445297-0 1987 Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. Anthralin 0-9 peroxiredoxin 5 Homo sapiens 38-59 2445297-4 1987 Because TR contains two reactive thiolate groups at its active site, this enzyme reacts with anthralin to form a covalent anthralin-TR complex causing irreversible enzyme deactivation. Anthralin 93-102 peroxiredoxin 5 Homo sapiens 8-10 2445297-4 1987 Because TR contains two reactive thiolate groups at its active site, this enzyme reacts with anthralin to form a covalent anthralin-TR complex causing irreversible enzyme deactivation. Anthralin 93-102 peroxiredoxin 5 Homo sapiens 132-134 2445297-4 1987 Because TR contains two reactive thiolate groups at its active site, this enzyme reacts with anthralin to form a covalent anthralin-TR complex causing irreversible enzyme deactivation. Anthralin 122-131 peroxiredoxin 5 Homo sapiens 8-10 2445297-4 1987 Because TR contains two reactive thiolate groups at its active site, this enzyme reacts with anthralin to form a covalent anthralin-TR complex causing irreversible enzyme deactivation. Anthralin 122-131 peroxiredoxin 5 Homo sapiens 132-134 2445297-6 1987 Keratinocyte cell cultures, grown from normal and psoriatic skin of one donor, revealed 24% and 42% inhibition of cell surface TR activity, respectively, in the presence of 2 X 10(-5)M anthralin. Anthralin 185-194 peroxiredoxin 5 Homo sapiens 127-129 3676090-3 1987 Catalase (50-100 units/ml) protected both PMNL migration and MNL proliferation from dithranol whilst ascorbate and cysteine (1 mM), which maintain dithranol in the biologically active reduced state, potentiated the inhibition. Anthralin 147-156 catalase Homo sapiens 0-8 3687577-0 1987 In vitro and in vivo antiinflammatory activities of C10 substituted anthralin derivatives. Anthralin 68-77 homeobox C10 Homo sapiens 52-55 3021863-1 1986 The effect of anthralin and its oxidation products danthrone and anthralin-dimer on the production of 5-lipoxygenase products (5-HETE, leukotriene B4, omega-oxidized LTB4) by Ca-ionophore A 23187-stimulated human neutrophils has been studied in vitro. Anthralin 14-23 arachidonate 5-lipoxygenase Homo sapiens 102-116 3021863-1 1986 The effect of anthralin and its oxidation products danthrone and anthralin-dimer on the production of 5-lipoxygenase products (5-HETE, leukotriene B4, omega-oxidized LTB4) by Ca-ionophore A 23187-stimulated human neutrophils has been studied in vitro. Anthralin 65-74 arachidonate 5-lipoxygenase Homo sapiens 102-116 3016102-0 1986 An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). Anthralin 116-125 calmodulin 1 Homo sapiens 66-76 3016102-0 1986 An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). Anthralin 127-136 calmodulin 1 Homo sapiens 66-76 3016102-4 1986 Dithranol (anthralin), however, whether freshly prepared or oxidized, produced substantial inhibition of CaM activity and was demonstrated to be a potent competitive antagonist of CaM, suggesting another possible therapeutic mode of action of dithranol in psoriasis. Anthralin 0-9 calmodulin 1 Homo sapiens 105-108 3016102-4 1986 Dithranol (anthralin), however, whether freshly prepared or oxidized, produced substantial inhibition of CaM activity and was demonstrated to be a potent competitive antagonist of CaM, suggesting another possible therapeutic mode of action of dithranol in psoriasis. Anthralin 0-9 calmodulin 1 Homo sapiens 180-183 3016102-4 1986 Dithranol (anthralin), however, whether freshly prepared or oxidized, produced substantial inhibition of CaM activity and was demonstrated to be a potent competitive antagonist of CaM, suggesting another possible therapeutic mode of action of dithranol in psoriasis. Anthralin 11-20 calmodulin 1 Homo sapiens 105-108 3016102-4 1986 Dithranol (anthralin), however, whether freshly prepared or oxidized, produced substantial inhibition of CaM activity and was demonstrated to be a potent competitive antagonist of CaM, suggesting another possible therapeutic mode of action of dithranol in psoriasis. Anthralin 11-20 calmodulin 1 Homo sapiens 180-183 3016102-4 1986 Dithranol (anthralin), however, whether freshly prepared or oxidized, produced substantial inhibition of CaM activity and was demonstrated to be a potent competitive antagonist of CaM, suggesting another possible therapeutic mode of action of dithranol in psoriasis. Anthralin 243-252 calmodulin 1 Homo sapiens 180-183 3088340-1 1986 10-Butyryl substituted 1,8-dihydroxyanthrone (butantrone) inhibited soybean lipoxygenase-1 irreversibly and more efficiently than its parent compound 1,8-dihydroxyanthrone (dithranol, anthralin) (IC50 values 0.090 mM and 1.1 mM, respectively). Anthralin 23-44 seed linoleate 13S-lipoxygenase-1 Glycine max 76-90 3731395-3 1986 In the absence of demonstrable adduct formation with DNA, the antipsoriatic, i.e. antiproliferative effect of anthralin, has been attributed to its action at the level of mitochondria or at the level of glucose-6-phosphate dehydrogenase which initiates the pentose phosphate shunt (cf. Anthralin 110-119 glucose-6-phosphate dehydrogenase Homo sapiens 203-236 7131282-0 1982 Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition. Anthralin 0-9 glucose-6-phosphate dehydrogenase Homo sapiens 36-69 2989375-1 1985 Treatment of human polymorphonuclear leukocytes (PMN) with anthralin (0.2-50 micrograms/ml) results in dose-dependent inhibition of nondirected as well as directed migration (chemotaxis) against the synthetic tripeptide N-formyl-methionyl-leucyl-phenylalanine (FMLP), the complement fragment C5a and leukotriene B4. Anthralin 59-68 formyl peptide receptor 1 Homo sapiens 261-265 2989375-4 1985 Specific binding of [3H]FMLP to neutrophil membrane receptors was impaired by anthralin at concentrations 5-10 fold higher than those which were inhibitory for cell function. Anthralin 78-87 formyl peptide receptor 1 Homo sapiens 24-28 3972578-12 1985 Fortunately, the staining due to dithranol brown can be reliably removed from certain textiles and from the bath tub or shower cabin by the use of hypochlorite. Anthralin 33-42 TUB bipartite transcription factor Homo sapiens 113-116 3972580-6 1985 Tar applied together with anthralin has recently been found to decrease the irritative qualities of anthralin. Anthralin 100-109 RNA binding motif protein 8A Homo sapiens 0-3 6744241-0 1984 Effect of 1,8-dihydroxy-9-anthrone (anthralin) on rat hepatic ornithine decarboxylase activity in vivo. Anthralin 10-34 ornithine decarboxylase 1 Rattus norvegicus 62-85 6744241-0 1984 Effect of 1,8-dihydroxy-9-anthrone (anthralin) on rat hepatic ornithine decarboxylase activity in vivo. Anthralin 36-45 ornithine decarboxylase 1 Rattus norvegicus 62-85 6744241-1 1984 Intraperitoneal injection of the non-phorbol tumor promoter anthralin (1,8-dihydroxy-9-anthrone) in male rats resulted in an increase of hepatic ornithine decarboxylase (ODC) activity. Anthralin 60-69 ornithine decarboxylase 1 Rattus norvegicus 145-168 6744241-1 1984 Intraperitoneal injection of the non-phorbol tumor promoter anthralin (1,8-dihydroxy-9-anthrone) in male rats resulted in an increase of hepatic ornithine decarboxylase (ODC) activity. Anthralin 60-69 ornithine decarboxylase 1 Rattus norvegicus 170-173 6744241-1 1984 Intraperitoneal injection of the non-phorbol tumor promoter anthralin (1,8-dihydroxy-9-anthrone) in male rats resulted in an increase of hepatic ornithine decarboxylase (ODC) activity. Anthralin 71-95 ornithine decarboxylase 1 Rattus norvegicus 145-168 6744241-1 1984 Intraperitoneal injection of the non-phorbol tumor promoter anthralin (1,8-dihydroxy-9-anthrone) in male rats resulted in an increase of hepatic ornithine decarboxylase (ODC) activity. Anthralin 71-95 ornithine decarboxylase 1 Rattus norvegicus 170-173 6744241-3 1984 The kinetics of anthralin dependent ODC induction differed markedly from that by either 12-O-tetradecanoylphorbol-13-acetate (TPA) or phenobarbital (PB) (Bisschop et al., Carcinogenesis 2 (1981) 1282). Anthralin 16-25 ornithine decarboxylase 1 Rattus norvegicus 36-39 6744241-4 1984 With anthralin a slow decrease of ODC back to control level is observed approximately within 22 h. In contrast, ODC induction mediated by other tumor promoters like TPA and PB decreased to control levels within 4-6 hours. Anthralin 5-14 ornithine decarboxylase 1 Rattus norvegicus 34-37 6744241-4 1984 With anthralin a slow decrease of ODC back to control level is observed approximately within 22 h. In contrast, ODC induction mediated by other tumor promoters like TPA and PB decreased to control levels within 4-6 hours. Anthralin 5-14 ornithine decarboxylase 1 Rattus norvegicus 112-115 6744241-6 1984 This effect lasted at least 10 h. ODC activity induction occurred in a dose-dependent manner being linear from 10-2000 micrograms anthralin/kg body wt. Anthralin 130-139 ornithine decarboxylase 1 Rattus norvegicus 34-37 6744241-7 1984 Pretreatment of the animals either with actinomycin D or with cycloheximide completely blocked anthralin mediated ODC induction suggesting that de novo ODC-mRNA synthesis and subsequent translation is involved in this process. Anthralin 95-104 ornithine decarboxylase 1 Rattus norvegicus 114-117 6744241-7 1984 Pretreatment of the animals either with actinomycin D or with cycloheximide completely blocked anthralin mediated ODC induction suggesting that de novo ODC-mRNA synthesis and subsequent translation is involved in this process. Anthralin 95-104 ornithine decarboxylase 1 Rattus norvegicus 152-155 6733038-3 1984 A possible explanation is that anthralin or an irritant product is metabolized by AHH activity in the skin. Anthralin 31-40 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 82-85 6733038-4 1984 Induction of AHH by coal tar increases its removal and reduces anthralin irritancy. Anthralin 63-72 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 13-16 7131282-2 1982 The time course for decomposition in solution has been correlated with that of the inhibition of glucose-6-phosphate dehydrogenase, one of the most widely documented biochemical properties associated with anthralin. Anthralin 205-214 glucose-6-phosphate dehydrogenase Homo sapiens 97-130 7131282-3 1982 Solutions of anthralin in aqueous buffer (37 degrees, pH 7.5, under light protection) completely within 4 hr giving the 10,10"-dimer (40%), no detectable 1,8-dihydroxy-9,10-anthraquinone, and a greatly increased potency of inhibition of glucose-6-phosphate dehydrogenase. Anthralin 13-22 glucose-6-phosphate dehydrogenase Homo sapiens 237-270 7131282-6 1982 The final solution had the characteristic color of anthralin-brown, contained the quinone (20%), and like decomposed aqueous solutions of anthralin, completely inhibited glucose-6-phosphate dehydrogenase. Anthralin 138-147 glucose-6-phosphate dehydrogenase Homo sapiens 170-203 7448761-0 1981 Paradoxical effect of anthralin on 12-O-tetradecanoylphorbol-13-acetate-induced mouse epidermal ornithine decarboxylase activity, proliferation, and tumor promotion. Anthralin 22-31 ornithine decarboxylase, structural 1 Mus musculus 96-119 6456755-0 1981 The inflammatory response to anthralin and its relation to aryl hydrocarbon hydroxylase. Anthralin 29-38 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 59-87 6165204-1 1981 Itch was measured quantitatively as nocturnal scratch in 12 patients with psoriasis treated with 8-methoxypsoralen and UVA and in 7 treated with dithranol. Anthralin 145-154 itchy E3 ubiquitin protein ligase Homo sapiens 0-4 7284258-0 1981 Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition. Anthralin 0-9 glucose-6-phosphate dehydrogenase Homo sapiens 36-69 423140-1 1979 Anthralin and its decomposition products were separated by both column chromatographic and TLC techniques. Anthralin 0-9 lipocalin 1 Homo sapiens 91-94 782506-4 1976 Dithranol, however, exerted a stronger inhibiting effect on glucose-6-phosphate dehydrogenase (-G-6-PDH) activity of human skin homogenates. Anthralin 0-9 glucose-6-phosphate dehydrogenase Homo sapiens 60-93 782506-4 1976 Dithranol, however, exerted a stronger inhibiting effect on glucose-6-phosphate dehydrogenase (-G-6-PDH) activity of human skin homogenates. Anthralin 0-9 hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase Homo sapiens 96-103 1183690-2 1975 The changes of anthralin under various physical conditions (temperature, ultraviolet irradiation) were investigated by biochemical assay (inhibition of G-6-PDH activity), by oxygen monitor (increased oxygen consumption in the presence of zinc ions), and by recording the absorption spectra. Anthralin 15-24 hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase Homo sapiens 152-159 33644099-8 2021 Results: Furin mRNA expression was significantly increased at baseline in the biologic (4.9 +- 2.6 fold, p < 0.0001) and in the dithranol group (2.7 +- 1.4 fold, p < 0.001) compared to controls. Anthralin 128-137 furin, paired basic amino acid cleaving enzyme Homo sapiens 9-14 33629779-0 2021 Induction of IL-1beta and antimicrobial peptides as a potential mechanism for topical dithranol. Anthralin 86-95 interleukin 1 alpha Mus musculus 13-21 33629779-6 2021 This contact response and disturbed barrier induced by dithranol might lead via a vicious loop between AMPs such as S100a8/a9 (that led to skin swelling itself after topical application) and cytokines such as IL-1beta to an immune suppressive environment in the skin. Anthralin 55-64 S100 calcium binding protein A8 (calgranulin A) Mus musculus 116-125 33629779-6 2021 This contact response and disturbed barrier induced by dithranol might lead via a vicious loop between AMPs such as S100a8/a9 (that led to skin swelling itself after topical application) and cytokines such as IL-1beta to an immune suppressive environment in the skin. Anthralin 55-64 interleukin 1 alpha Mus musculus 209-217 4447386-0 1974 The inhibition of glucose-6-phosphate dehydrogenase activity by dithranol (anthralin), zinc ions and/or salicylic acid. Anthralin 64-73 glucose-6-phosphate dehydrogenase Homo sapiens 18-51 4447386-0 1974 The inhibition of glucose-6-phosphate dehydrogenase activity by dithranol (anthralin), zinc ions and/or salicylic acid. Anthralin 75-84 glucose-6-phosphate dehydrogenase Homo sapiens 18-51 32696216-5 2020 Indeed, daily dithranol treatment of the orofacial skin for 3-5 days increased the number of macrophages and Iba1 protein expression in the maxillary subregion of the ipsilateral ganglion. Anthralin 14-23 allograft inflammatory factor 1 Rattus norvegicus 109-113 32696216-8 2020 Subsequently, when a 5-day-long anti-inflammatory corticosteroid therapy was employed on the previously dithranol-treated orofacial skin, Iba1 immunoreactivity was substantially reduced in the ipsilateral ganglion. Anthralin 104-113 allograft inflammatory factor 1 Rattus norvegicus 138-142 32484435-3 2020 Top differentially expressed genes in the early response to dithranol belonged to keratinocyte and epidermal differentiation pathways and IL-1 family members (i.e. IL36RN) but not elements of the IL-17/IL-23 axis. Anthralin 60-69 interleukin 36 receptor antagonist Homo sapiens 164-170 32484435-3 2020 Top differentially expressed genes in the early response to dithranol belonged to keratinocyte and epidermal differentiation pathways and IL-1 family members (i.e. IL36RN) but not elements of the IL-17/IL-23 axis. Anthralin 60-69 interleukin 23 subunit alpha Homo sapiens 202-207 21882816-7 2011 Moreover, the 1:1 mixture exhibited a reduced inflammatory effect compared to dithranol alone, as reflected by the upregulation of cyclooxygenase-2 by 45% and 136%, respectively. Anthralin 78-87 prostaglandin-endoperoxide synthase 2 Homo sapiens 131-147 26895458-0 2016 Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK). Anthralin 0-9 tumor necrosis factor Homo sapiens 61-64 26895458-0 2016 Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK). Anthralin 0-9 TNF superfamily member 12 Homo sapiens 97-102 26895458-3 2016 The aim of the study was to assess serum levels of TWEAK in psoriatic patients before and after topical treatment with dithranol in relation to the clinical activity of the disease. Anthralin 119-128 TNF superfamily member 12 Homo sapiens 51-56 26895458-11 2016 Moreover, dithranol topical treatment caused further increase in serum TWEAK. Anthralin 10-19 TNF superfamily member 12 Homo sapiens 71-76 25792810-5 2015 Among these analogues, em08red (1,8-dihydroxy-9(10H)-anthracenone) demonstrated potent antiproliferative activity against all three tested ErbB2-overexpressing cell lines, ie, FaDu, HSC3, and OECM1. Anthralin 32-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 139-144 25792810-5 2015 Among these analogues, em08red (1,8-dihydroxy-9(10H)-anthracenone) demonstrated potent antiproliferative activity against all three tested ErbB2-overexpressing cell lines, ie, FaDu, HSC3, and OECM1. Anthralin 32-65 DnaJ heat shock protein family (Hsp40) member B7 Homo sapiens 182-186 23079823-0 2012 Dithranol downregulates expression of Id1 mRNA in human keratinocytes in vitro. Anthralin 0-9 inhibitor of DNA binding 1, HLH protein Homo sapiens 39-42 23079823-3 2012 We investigated the effect of the antipsoriatic drug dithranol on mRNA and protein expression levels of Id1 in the HaCaT keratinocyte cell line. Anthralin 53-62 inhibitor of DNA binding 1, HLH protein Homo sapiens 104-107 23079823-6 2012 Changes in normalized Id1 mRNA levels were observed only after 4 h of dithranol treatment. Anthralin 70-79 inhibitor of DNA binding 1, HLH protein Homo sapiens 22-25 23079823-7 2012 There was reduced expression of Id1 mRNA transcripts in the HaCaT cells treated with 0.1 mug/mL dithranol, but the reduction was not significant. Anthralin 96-105 inhibitor of DNA binding 1, HLH protein Homo sapiens 32-35 23079823-8 2012 The expression of Id1 mRNA was significantly downregulated (almost 50%) when 0.25 or 0.5 mug/mL dithranol was applied to the HaCaT cells. Anthralin 96-105 inhibitor of DNA binding 1, HLH protein Homo sapiens 18-21 28673488-11 2017 Furthermore, anthralin directly inhibits DEFB4 expression in vitro and in vivo, while other antimicrobial peptides and cytokines studied like IL-6 and IL-8 are regulated differently in vitro and in vivo. Anthralin 13-22 defensin beta 4A Homo sapiens 41-46 28673488-12 2017 CONCLUSIONS: Our results show that anthralin directly regulates DEFB4A expression. Anthralin 35-44 defensin beta 4A Homo sapiens 64-70 22370944-0 2012 Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Anthralin 35-44 transcription factor 3 Homo sapiens 48-51 22370944-0 2012 Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Anthralin 35-44 caspase 9 Homo sapiens 56-65 22370944-4 2012 We examined the molecular effects of dithranol on the mRNA and protein expression levels of E2A and caspase-9 in the HaCaT keratinocyte cell line. Anthralin 38-47 transcription factor 3 Homo sapiens 93-96 22370944-4 2012 We examined the molecular effects of dithranol on the mRNA and protein expression levels of E2A and caspase-9 in the HaCaT keratinocyte cell line. Anthralin 38-47 caspase 9 Homo sapiens 102-111 22370944-8 2012 We found that dithranol treatment in the range of 0.25-0.5 mug/mL slightly upregulated the mRNA expression of E2A and caspase-9 approximately 1.5- and 1.2-fold, respectively. Anthralin 14-23 transcription factor 3 Homo sapiens 111-128 17664023-3 2008 We analyzed the calmodulin (CaM) gene expression in these nuclei after dithranol-induced inflammation and subsequent treatment with corticosteroid in the infraorbital skin. Anthralin 71-80 calmodulin 1 Rattus norvegicus 16-26 21268127-8 2011 When DMBA/anthralin was used, BK5.EP1 mice produced more tumors than WT mice, as well as a ninefold increase in carcinomas, indicating that the tumor response is dependent on the type of tumor promoter agent used. Anthralin 10-19 prostaglandin E receptor 1 (subtype EP1) Mus musculus 34-37 17664023-3 2008 We analyzed the calmodulin (CaM) gene expression in these nuclei after dithranol-induced inflammation and subsequent treatment with corticosteroid in the infraorbital skin. Anthralin 71-80 calmodulin 1 Rattus norvegicus 28-31 17664023-4 2008 CaM gene-specific mRNA populations were detected through quantitative image analysis of the distribution of CaM gene-specific riboprobes in brain stem cryostat sections of control rats and rats chronically treated with dithranol, corticosteroid or both. Anthralin 219-228 calmodulin 1 Rattus norvegicus 0-3 17664023-8 2008 Subsequent corticosteroid treatment reversed the stimulatory effects of dithranol on the expression of all the CaM genes in the Mo5, but was without significant effects on the CaM I and II genes, or even increased the CaM III mRNA contents in the Pr5. Anthralin 72-81 calmodulin 1 Rattus norvegicus 111-114 17583568-9 2007 This resistance phenotype appears to be restricted to phorbol ester promotion because K14.COX2 mice developed six times more tumors than wild-type mice when anthralin was used as the tumor promoter. Anthralin 157-166 keratin 14 Mus musculus 86-89 17583568-9 2007 This resistance phenotype appears to be restricted to phorbol ester promotion because K14.COX2 mice developed six times more tumors than wild-type mice when anthralin was used as the tumor promoter. Anthralin 157-166 cytochrome c oxidase II, mitochondrial Mus musculus 90-94 17011532-0 2006 Dithranol abolishes UCH-L1 immunoreactivity in the nerve fibers of the rat orofacial skin. Anthralin 0-9 ubiquitin C-terminal hydrolase L1 Rattus norvegicus 20-26 17011532-5 2006 The results revealed a complete loss of UCH-L1 immunoreactivity in the dithranol-treated animals. Anthralin 71-80 ubiquitin C-terminal hydrolase L1 Rattus norvegicus 40-46 17011532-9 2006 We conclude that dithranol, incidentally similarly to psoriasis, causes inflammation and abolishes UCH-L1 immunoreactivity in the rat orofacial skin in a corticosteroid-reversible manner. Anthralin 17-26 ubiquitin C-terminal hydrolase L1 Rattus norvegicus 99-105 17011532-10 2006 This phenomenon may be due to the ability of dithranol to cause oxidative damage to the UCH-L1 protein, and to the antioxidant activity of the corticosteroids countering this effect. Anthralin 45-54 ubiquitin C-terminal hydrolase L1 Rattus norvegicus 88-94 16973179-7 2006 For compound 13, 15 and dithranol (used as a model antipsoriatic drug), a dose-dependent downregulation of TNFalpha mRNA was found. Anthralin 24-33 tumor necrosis factor Homo sapiens 107-115